Glaukos Corporation · NYSE:GKOS
Glaukos — Q3 2022 Earnings Presentation
7 slides from Glaukos's earnings presentation, Nov 2, 2022
Slide 1: We'll Go First
WE'LL GO FIRST Innovation is at the core of everything we do. At Glaukos, ‘we push the limits of science and technology to solve unmet needs in chronic eye diseases. GLAUKOS TRANSFORMING VISION
Slide 2: Franchise Revenue Performance
Franchise Revenue Performance
Slide 3: 3Q 2022 Revenue Mix
3Q 2022 Revenue Mix Corneal Health $17.5M U.S. Glaucoma $37.2M International Glaucoma $16.5M
Slide 4: Glaukos Pipeline Summary
Glaukos Pipeline Summary Market Platform Product Indication U.S, Status (1) iPRIME Delivery of viscoelastic during ophthalmic surgery FDA Clearance Received iAccess Manual cutting of TM during ophthalmic surgery FDA Clearance Received ‘Mild-to-moderate primary open-angle glaucoma in inva istent /ist
Slide 5: Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles On September 7, 2022, Glaukos announced topline data for both Phase 3 pivotal trials of iDose TR that successfu
Slide 6: Other Important Updates
Other Important Updates Ø 1 Million iStent Milestone o On September 6, 2022, Glaukos announced a significant milestone as its iStent family of technologies surpassed being implanted in more than one million procedures worldwide. o This market-leading milestone is a testament to the decades of inve
Slide 7: Additional Information
Additional Information